Esperovax is pioneering the development of targeted oral mRNA vaccines, focusing on a proprietary platform known as Egress™. This innovative technology allows for the delivery of mRNA vaccines in the form of small oral capsules, targeting immune cells in the gastrointestinal tract. The company aims to create vaccines that are not only effective but also safer and more cost-efficient than traditional injectable vaccines. Esperovax's approach includes the use of yeast-based virus-like particles (VLPs) to enhance the immunogenic response, demonstrating clinical safety and efficacy in preliminary studies. This platform holds promise for a wide range of applications, including the prevention and treatment of infectious diseases in both humans and animals.

In addition to its vaccine development efforts, Esperovax has secured exclusive licensing for a novel yeast-based manufacturing technology from the University of Michigan. This technology is designed to facilitate continuous production and purification of vaccines, significantly improving yield and reducing costs. The company has also been awarded funding to advance its oral COVID-19 RNA vaccine candidate, which is part of a broader initiative to address public health challenges through innovative vaccine solutions. With a

United States

Fighting the world’s most devastating diseases through the innovative power of targeted oral mRNA vaccines.

Esperovax

Company Details